Literature DB >> 26646120

Occult Uterine Sarcoma and Leiomyosarcoma: Incidence of and Survival Associated With Morcellation.

Tina Raine-Bennett1, Lue-Yen Tucker, Eve Zaritsky, Ramey D Littell, Ted Palen, Romain Neugebauer, Allison Axtell, Peter M Schultze, David W Kronbach, Julia Embry-Schubert, Alvina Sundang, Kimberly Bischoff, Amy L Compton-Phillips, Scott E Lentz.   

Abstract

OBJECTIVE: To estimate the incidence of occult uterine sarcoma and leiomyosarcoma in hysterectomies for leiomyomas and the risk associated with their morcellation.
METHODS: We conducted a population-based cohort study. All uterine sarcomas from 2006-2013 in an integrated health care system were identified. Age- and race-specific incidences of occult uterine sarcoma were calculated. Kaplan-Meier survival analysis was performed. Crude and adjusted risk ratios of recurrence and death associated with morcellation at 1, 2, and 3 years were estimated using Poisson regression with inverse probability weighting.
RESULTS: There were 125 hysterectomies with occult uterine sarcomas identified among 34,728 hysterectomies performed for leiomyomas. The incidence of occult uterine sarcoma and leiomyosarcoma was 1 of 278 or 3.60 (95% confidence interval [CI] 2.97-4.23) and 1 of 429 or 2.33 (95% CI 1.83-2.84) per 1,000 hysterectomies. For stage I leiomyosarcoma (n=111), eight (7.2%) were power and 27 (24.3%) nonpower-morcellated. The unadjusted 3-year probability of disease-free survival for no morcellation, power and nonpower morcellation was 0.54, 0.19, and 0.51, respectively (P=.15); overall survival was 0.64, 0.75, and 0.68, respectively (P=.97). None of the adjusted risk ratios for recurrence or death were significant except for death at 1 year for power and nonpower morcellation groups combined (6/33) compared with no morcellation (4/76) (5.12, 95% CI 1.33-19.76, P=.02). We had inadequate power to infer differences for all other comparisons including 3-year survival and power morcellation.
CONCLUSION: Morcellation is associated with decreased early survival of women with occult leiomyosarcomas. We could not accurately assess associations between power morcellation and 3-year survival as a result of small numbers.

Entities:  

Mesh:

Year:  2016        PMID: 26646120     DOI: 10.1097/AOG.0000000000001187

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  24 in total

1.  Laparoscopic hysterectomy with morcellation vs abdominal hysterectomy for presumed fibroids: an updated decision analysis following the 2014 Food and Drug Administration safety communications.

Authors:  Matthew T Siedhoff; Kemi M Doll; Daniel L Clarke-Pearson; Sarah E Rutstein
Journal:  Am J Obstet Gynecol       Date:  2016-11-24       Impact factor: 8.661

2.  Association Between Power Morcellation and Mortality in Women With Unexpected Uterine Cancer Undergoing Hysterectomy or Myomectomy.

Authors:  Xiao Xu; Haiqun Lin; Jason D Wright; Cary P Gross; Francis P Boscoe; Lindsey M Hutchison; Peter E Schwartz; Vrunda B Desai
Journal:  J Clin Oncol       Date:  2019-09-16       Impact factor: 44.544

3.  Prognostic factors and survival of patients with uterine sarcoma: a German unicenter analysis.

Authors:  Alexandra Huss; Maximilian Klar; Mir Fuad Hasanov; Ingolf Juhasz-Böss; Michaela Bossart
Journal:  Arch Gynecol Obstet       Date:  2022-07-03       Impact factor: 2.344

4.  A novel morphology-based risk stratification model for stage I uterine leiomyosarcoma: an analysis of 203 cases.

Authors:  David B Chapel; Aarti Sharma; Ricardo R Lastra; Livia Maccio; Emma Bragantini; Gian Franco Zannoni; Suzanne George; Bradley J Quade; Carlos Parra-Herran; Marisa R Nucci
Journal:  Mod Pathol       Date:  2022-02-04       Impact factor: 7.842

Review 5.  Advances in the Preoperative Identification of Uterine Sarcoma.

Authors:  Junxiu Liu; Zijie Wang
Journal:  Cancers (Basel)       Date:  2022-07-20       Impact factor: 6.575

6.  Impact of Intraoperative Tumor Spillage in Uterine Leiomyosarcoma: a Retrospective Single-Institution Analysis.

Authors:  Viral Patel; Anupama Rajanbabu; Indu R Nair; Pramod R Pillai; Greeshma C Ravindran
Journal:  Indian J Surg Oncol       Date:  2021-08-07

7.  Incidence of sarcoma in patients undergoing hysterectomy for benign indications: a population-based study.

Authors:  Francesco Multinu; Jvan Casarin; Lucia Tortorella; Yajue Huang; Amy Weaver; Stefano Angioni; Gian Benedetto Melis; Andrea Mariani; Elizabeth A Stewart; Shannon K Laughlin-Tommaso
Journal:  Am J Obstet Gynecol       Date:  2018-11-14       Impact factor: 8.661

8.  Sarcoma of the Uterus. Guideline of the DGGG and OEGGG (S2k Level, AWMF Register Number 015/074, February 2019).

Authors:  Dominik Denschlag; Sven Ackermann; Marco Johannes Battista; Wolfgang Cremer; Gerlinde Egerer; Markus Follmann; Heidemarie Haas; Philipp Harter; Simone Hettmer; Lars-Christian Horn; Ingolf Juhasz-Boess; Karin Kast; Günter Köhler; Thomas Kröncke; Katja Lindel; Peter Mallmann; Regine Meyer-Steinacker; Alexander Mustea; Edgar Petru; Peter Reichardt; Dietmar Schmidt; Hans-Georg Strauss; Clemens Tempfer; Falk Thiel; Uwe Ulrich; Thomas Vogl; Dirk Vordermark; Paul Gass; Matthias W Beckmann
Journal:  Geburtshilfe Frauenheilkd       Date:  2019-10-22       Impact factor: 2.915

9.  Endometrial Sampling for Preoperative Diagnosis of Uterine Leiomyosarcoma.

Authors:  Rosanne M Kho; Vrunda B Desai; Peter E Schwartz; Jason D Wright; Cary P Gross; Lindsey M Hutchison; Francis P Boscoe; Haiqun Lin; Xiao Xu
Journal:  J Minim Invasive Gynecol       Date:  2021-07-13       Impact factor: 4.137

10.  Inbag Morcellation Applied to the Laparoscopic Surgery of Leiomyoma: A Randomized Controlled Trial.

Authors:  Chloe Bensouda-Miguet; Erdogan Nohuz; Emanuele Cerruto; Annie Buenerd; Beatrice Nadaud; Stephanie Moret; Gautier Chene
Journal:  Biomed Res Int       Date:  2021-05-26       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.